Reversing Medications That Cause Bleeding



Similar documents
The Brave New (Anticoagulant) World

INITIATION OF THERAPY Patient-specific considerations for initiation of apixaban therapy include the following:

INITIATION OF THERAPY Patient-specific considerations for initiation of rivaroxaban therapy include the following:

TABLE 1. Initial Rivaroxaban Dosing Indication Renal Function a (CrCL ml/min) Recommended Dose b

How To Know What A Pressure Ulcer Is

Xabans Good for What Ails Ya? Brian Tiffany, MD, PhD, FACEP Dept of Emergency Medicine Chandler Regional Medical Center Mercy Gilbert Medical Center

Reversal of Antiplatelet and Anticoagulant Therapy: What You Need To Know. Ronald Walsh, MD Chief Medical Officer Community Blood Services

Making Sense of the Newer Anticoagulants

Anticoagulation and Reversal

Active & Retiree Plan: Trustees of the Milwaukee Roofers Health Fund Coverage Period: 06/01/ /31/2016 Summary of Benefits and Coverage:

High Risk Emergency Medicine

Polynomial Functions. Polynomial functions in one variable can be written in expanded form as ( )

Treatment Spring Late Summer Fall Mean = 1.33 Mean = 4.88 Mean = 3.

Stop the Bleeding: Management of Drug-induced Coagulopathy. Stacy A. Voils, PharmD, BCPS Critical Care Specialist, Neurosurgery

Health insurance marketplace What to expect in 2014

Health insurance exchanges What to expect in 2014

Utilization of Smoking Cessation Benefits in Medicaid Managed Care,

New Anticoagulants: What to Use What to Avoid

Humana Critical Illness/Cancer

3/3/2015. Patrick Cobb, MD, FACP March 2015

Econ 4721 Money and Banking Problem Set 2 Answer Key

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1)

Hematopoietic stem cell transplantation

Quick Reference Guide: One-time Account Update

New Anticoagulation Options for Stroke Prevention in Atrial Fibrillation. Joy Wahawisan, Pharm.D., BCPS April 25, 2012

Target: 10 mg/day within several days Schizophrenia in adolescents (2.1) Oral: Start at mg once daily; Target: 10 mg/day

Objective: Erectile dysfunction and depression are highly associated. Previous studies have shown benefits of phosphodiesterase-5

Warnings and Precautions Never Share a Humalog KwikPen, Cartridge, Reusable Pen Compatible with Lilly 3 ml Cartridges, or Syringe Between

The Role of the Newer Anticoagulants

Anthem Blue Cross Life and Health Insurance Company University of Southern California Custom Premier PPO 800/20%/20%

Or more simply put, when adding or subtracting quantities, their uncertainties add.

New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding - A Systematic Review and Meta-Analysis

AJP in Advance. Published May 2, 2011 (doi: /appi.ajp ) Article

5/21/2012. Perioperative Use Issues. On admission: During hospitalization:

Critical Bleeding Reversal Protocol

Graphs on Logarithmic and Semilogarithmic Paper

LAMC Reversal Agent Guideline for Anticoagulants Time to resolution of hemostasis (hrs) Therapeutic Options

PROF. BOYAN KOSTADINOV NEW YORK CITY COLLEGE OF TECHNOLOGY, CUNY

Epilepsy & Behavior 15 (2009) Contents lists available at ScienceDirect. Epilepsy & Behavior. journal homepage:

Health insurance exchanges What to expect in 2014

Schedule of benefits Benefits Preferred Advantage Basic Enhanced C

Small Businesses Decisions to Offer Health Insurance to Employees

Warm-up for Differential Calculus

Impact of new (direct) oral anticoagulants in patient blood management

Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation

COMPARISON OF SOME METHODS TO FIT A MULTIPLICATIVE TARIFF STRUCTURE TO OBSERVED RISK DATA BY B. AJNE. Skandza, Stockholm ABSTRACT

baby on the way, quit today

Anticoagulation Essentials! Parenteral and Oral!

EXPERIMENTAL AND THERAPEUTIC MEDICINE 8: , 2014

Section 7-4 Translation of Axes

274 Chapter 13. Chapter 13

Update on Antiplatelets and anticoagulants. Outlines. Antiplatelets and Anticoagulants 1/23/2013. Timir Paul, MD, PhD

Answer, Key Homework 10 David McIntyre 1

3/25/14. To Clot or Not What s New In Anticoagulation? Clotting Cascade. Anticoagulant drug targets. Anita Ralstin, MS CNS CNP. Heparin.

48 th Annual Meeting. Non-VKA Oral Anticoagulants: Prevention & Treatment of Bleeding. Terminology. Disclosure. Public Health Impact.

Anticoagulant Reversal

Operations with Polynomials

Rate and Activation Energy of the Iodination of Acetone

P.3 Polynomials and Factoring. P.3 an 1. Polynomial STUDY TIP. Example 1 Writing Polynomials in Standard Form. What you should learn

OHIO CRIMINAL SENTENCING COMMISSION 65 South Front Street Second Floor Columbus Telephone: (614) Fax: (614)

Warfarin and Novel Anti-Coagulants: Management Before and After the Cath Lab

Math 135 Circles and Completing the Square Examples

Devang M. Desai, MD, FACC, FSCAI Chief of Interventional Cardiology Director of Cardiac Catheterization Lab St. Mary s Hospital and Regional Medical

See 17 for PATIENT COUNSELING INFORMATION. Revised: 11/2013

Review of Newer Antiplatelets, Antithrombotics and Reversal

Reversing the New Anticoagulants

Speaker Disclosure. Outline. Pharmacist Objectives. Patient Case. Outline 9/4/2014

Session 3 Topics. Argatroban. Argatroban. Drug Use and Adverse Effects. Laboratory Monitoring of Anticoagulant Therapy

How To Treat Aneuricaagulation

Pure C4. Revision Notes

What we all Needs to Know about New and Old Anticoagulant and Antiplatelet Drugs. None related to this presentation 11/22/2012

Factoring Polynomials

DlNBVRGH + Sickness Absence Monitoring Report. Executive of the Council. Purpose of report

Physics 43 Homework Set 9 Chapter 40 Key

FAULT TREES AND RELIABILITY BLOCK DIAGRAMS. Harry G. Kwatny. Department of Mechanical Engineering & Mechanics Drexel University

Helicopter Theme and Variations

How To Increase Warfarin

New Oral AntiCoagulants (NOAC) in 2015

ADVATE [Antihemophilic Factor (Recombinant)] Lyophilized Powder for Reconstitution for Intravenous Injection Initial U.S.

Use Geometry Expressions to create a more complex locus of points. Find evidence for equivalence using Geometry Expressions.

GUIDELINES IN ANTIPLATELET AND ANTICOAGULATION RX IN CARDIAC SURGERY

Appendix D: Completing the Square and the Quadratic Formula. In Appendix A, two special cases of expanding brackets were considered:

Exponential and Logarithmic Functions

Advanced Issues in Peri-Operative VTE Prevention

Vendor Rating for Service Desk Selection

Advances in An+coagula+on

Comparison between New Oral Anticoagulants and Warfarin

Many national organizations

How does warfarin work? We know itʼs a vitamin k antagonist, but what does that mean? What's really getting antagonized?

Program Objectives. Why Use Anticoagulants? 6/5/2014

DVT/PE Management with Rivaroxaban (Xarelto)

Traditional anticoagulants

Dr Gordon Royle Haematologist, Middlemore Hospital

Transcription:

Reversing Medictions Tht Cuse Bleeding Dine M. Birnbumer, M.D., FACEP Professor of Medicine University of Cliforni, Los Angeles Senior Fculty Deprtment of Emergency Medicine Hrbor-UCLA Medicl Center The Agony nd The Ecstsy of Pltelets nd Clotting The Ecstsy We cn chnge how people clot We cn prevent strokes We cn prevent DVT nd PE We cn improve crdic outcomes in ACS The Agony nd The Ecstsy of Pltelets nd Clotting The Agony Vrible efficcy Nrrow therpeutic index Potentil drug / food interctions Need for monitoring Bleed risk Antidotes nd reversibility The Agony nd The Ecstsy of Pltelets nd Clotting We need better drugs nd guess wht! We hve them! But better HOW???? Newer is Better Right? Depends on wht color glsses you re looking through As crdiologist? As neurologist? As n emergency physicin? Or s ptient? Issues with the New Agents For emergency prctitioners Cn we mesure their ctivity if we need to? Cn we reverse their effects in cses of bleeding requiring emergency cre? 1

Will NOT cover Dltprin (Frgmin) Fondprinux (Arixtr) Aspirin Tried nd true Poisons pltelet for life of the pltelet 5-10 dys Cn reverse with (nd/or) Pltelet concentrte DDAVP (0.3-0.4 µg/kg) Reversl in 15-30 minutes Clopidigrel nd Prsugrel Thienopyridine derivtives Block ADP receptor on pltelet Cn be effectively combined with spirin in some cses Increses bleeding risk signficntly Therefore, in some cses the combintion overll is not worth the risk Clopidigrel nd Prsugrel Clopidigrel (Plvix ) vs. Prsugrel (Effient ) Prsugrel hs stronger ntipltelet effect In generl More effective thn clopidigrel More mjor bleeding events thn clopidigrel Clopidigrel nd Prsugrel Cn reverse with (nd/or) Pltelet concentrte (15-30 minutes) Mybe dd DDAVP (0.3-0.4 µg/kg) Reversl in 15-30 minutes 2

ETRINSIC Binds to ntithrombin Potentites inhibition of thrombin nd fctor (by 1000-fold) Hlf-life of 60-90 minutes If stopped, hemostsis restored in 3-4 hr Reversed with protmine sulfte Dosing is 1 mg protmine per 100 units heprin given in lst 2-3 hours Usully 25-30 mg effective Mximum dose 50 mg Hlf-life 10 minutes Reversl is immedite My cuse llergic rection Low Moleculr Weight Low dose vs. high dose hve differing hlf-lives Both, however, lst longer thn regulr unfrctionted IV heprin Low Moleculr Weight If stopped, hemostsis restored in 12-24 hours Prtilly reversed by protmine sulfte 1 mg protmine per 100 units LMWH given in the lst 8 hours Mximum dose 50 mg Hlf-life 10 minutes; infusion my be needed Reversl, when effective, is immedite Vitmin K Antgonists 3

ETRINSIC Vit K Antgonists: Long experience with its use Blocks production of vitmin K dependent cogultion fctors (II, VII, I, ) Induces fctor deficiency stte Mens we my be ble to replce these fctors to reverse it Risk of mjor bleeding 0.5% per yer Risk of ICH is 0.2% per yer Vit K Antgonists: Risk of bleeding directly relted to height of INR Over 3.0, incidence doubles when compred to INR of 2.0-3.0 Risk of bleeding increses with codministrtion of ntipltelet gents Elderly hve two-fold incresed risk of ICH Vit K Antgonists: Hemostsis fter cesstion: 60-80 hours Reversl Vitmin K (dose depends on INR nd body wgt) IV: Reversl in 12-16 hours PO: Reversl in 24 hours FFP lrge mounts needed my be prohibitory PCCs reversl is immedite Wht is PCC? Complex Concentrte Briplex, Octplex 4 fctors Profilnine, Bebulin 3 fctors Contin multiple fctors, including prothrombin Hve more prothrombin thn FFP Fctor Inhibitors The xbns 4

ETRINSIC Fctor Inhibitors Orl Fctor inhibitors relto (pproved 7/11/11) Eliquis (pproved 12/30/12) Cnnot mesure nticogulnt effect Fctor Inhibitors relto (pproved 7/11/11) Surgicl DVT prophylxis Stroke prevention in nonvlvulr AF DVT/PE tretment ACS coming down the pike? Eliquis (pproved 12/30/12) Stroke prevention in nonvlvulr AF Edoxbn - Lixin Fctor Inhibitors relto Hlf-life 5-13 hours Eliquis Hlf-life 9-14 hours Edoxbn - Lixin Hlf-life 9-10 hours Fctor Inhibitors Generl efficcy / sfety dt (so fr) Compred with LMWH (DVT prophylxis) Lower bleeding risk Similr efficcy Compred with wrfrin (stroke in AF) Noninferior to wrfrin Lower rte of bleeding (2.1 % vs 3%) Fctor Inhibitors Reversl in bleeding Cesstion of mediction will reverse nticogulnt effect How long it tkes depends on hlf-life All re too long in cses of serious bleeding Immedite reversl No ntidotes found to dte Fctor inhibitor ntidotes would be useful, being investigted but not vilble to dte 5

ETRINSIC Direct Thrombin Inhibitors Hirudin ws prototype (leech spit) Prdx (ppr. Oct 2010) Competitive, direct thrombin inhibitor Approved for Stroke prevention in A Fib (2010) DVT prophylxis fter surgery (ACS coming soon?) Hlf-life 12-17 hours Prdx Benefits over wrfrin Anticogultion immedite No trnsient hypercogulble stte Does not require blood testing to monitor Miniml interctions with food/drugs Not recommended in renl filure or in ptients with impired heptic function Prdx For stroke prevention As effective s wrfrin Risk of mjor bleeding sme or less thn wrfrin (round 3%) Older ptients hd higher risk of bleeding Issues for emergencies Cnnot follow blood testing for nticogultion effect (non-liner effect) Cogultion studies re elevted, but do not correlte with bleeding risk (Note: These rtes were in trils; we ll see wht hppens in the rel world ) 6

Issues for emergencies Tretment of bleeding Supportive cre prbcs, IV fluids, stopping bleeding by direct mens Activting thrombin Removing dbigtrn Not highly protein bound 4 hours of dilysis removes 68% of dbigtrn Direct Thrombin (II)Inhibitors Issues for emergencies Tretment of bleeding Activting thrombin My be impossible FFP hs miniml prothrombin not likely useful PCCs my be useful but poorly studied to dte rvii not dequtely studied nd unlikely useful Not useful: Cryoprecipitte, protmine, DDAVP, trnexmic cid, minocproic cid Time to hemostsis fter stopping tking mediction Antidote Time to reversl 3-4 hr Protmine sulfte Immedite LMW 12-24 hr Protmine (prtil) Immedite Pentscchrides Fond: 24-30 hr Idrpr: 5-15k Recomb VII Vit K Antg : 60-80 hr Vit K IV Vit K orl PCCs Orl thrombin nd fctor inhibitors Usully within 12 hr Recomb fct Thrombin???? Immedite thrombin genertion 12-16 hr 24 hr Immedite Unknown Thnk You For Your Attention! Any Questions? Aspirin 5-10 dys DDAVP, pltelets 15-30 minutes Clopidogrel Prsugrel 1-2 dys Pltelets, mybe DDAVP 15-30 minutes 7